Venous Thrombotic and Thromboembolic Considerations in Stroke: An Expert Meeting Report on Future Directions for Clinical Trials.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vikulova Diana N, Dizonno Vanessa, Zhou Lily, Gorman Johnathon, Lun Ronda, Ignacio Katrina Hd, Bushnell Cheryl D, Ganesh Aravind, Katsanos Aristedis H, Sposato Luciano A, Rosa Sara Db, Fuerte-Hortigon Alejandro, Aguiar de Sousa Diana, Carcel Cheryl, Singh Nishita, Wan Tony, Samuelson Bannow Bethany T, Bian Hetao, Chen Chen, Coutinho Jonathan M, Demchuk Andrew M, Doshi Darshan, Farhoudi Mehdi, Fonseca Ana Catarina, Fu Vivian, Heldner Mirjam R, Ouyang Menglu, Ramage Emily R, Sebastian Ivy, Leker Ronen R, Anderson Craig S, Menon Bijoy K, Field Thalia S
Аннотация
PURPOSE: We therefore convened experts across both stroke neurology and thrombosis medicine fields to examine these conditions under a unifying venous theme and define priorities for future clinical trials.
METHODS: Thirty-two stroke and thrombosis clinicians and researchers identified research priorities across three domains: prevention of VTE after stroke, secondary prevention after PFO-related stroke, and acute and long-term management of CVT. Structured discussions were guided by the PICO (Population, Intervention, Comparison, Outcome) framework, followed by a Delphi survey to establish consensus. Priority questions centered on the balance between thrombosis prevention and bleeding risk and the optimal timing, duration, and choice of DVT/PE prophylaxis after stroke; the optimal antithrombotic strategy for patients awaiting or forgoing PFO closure; and, for CVT, the role of endovascular therapy in severe disease and the optimal duration of secondary prevention (Graphical Abstract). Across domains, the group prioritized pragmatic and platform trial designs, integration with international registries to address the rarity of CVT, and patient-oriented outcomes that extend beyond functional recovery.
CONCLUSIONS: By considering these venous conditions together and bridging stroke and thrombosis disciplines, this work defines priority questions to address persistent evidence gaps, harmonize practice, and improve patient-centered outcomes.